7.77  0.18 (2.37%)		04-23 16:00
Open: 7.77 High: 7.77 Volume: 18,341		Pre. Close: 7.59 Low: 7.77 Market Cap: 38(M)

Short term
Mid term
Targets	6-month :	9.59	1-year :	10.31
Resists	First :	8.21	Second :	8.82
Pivot price	7.7
Supports	First :	7.23	Second :	6.01
MAs	MA(5) :	7.69	MA(20) :	7.79
	MA(100) :	8	MA(250) :	8.65
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	60.7	D(3) :	48.3
RSI	RSI(14): 49.3
52-week	High :	10	Low :	6.55

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ DXR ] has closed below upper band by 42.4%. Bollinger Bands are 21.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.78 - 7.83	7.83 - 7.86
Low:	7.65 - 7.71	7.71 - 7.76
Close:	7.69 - 7.78	7.78 - 7.84

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Wed, 23 Apr 2025
Daxor stock hits 52-week low at $6.83 amid market challenges - MSN

Tue, 22 Apr 2025
Daxor Corporation to Exhibit at the 45th International - GlobeNewswire

Tue, 22 Apr 2025
Revolutionary Blood Volume Analysis: How Daxor's 98% Accurate Tech is Transforming Heart and Lung Care - Stock Titan

Mon, 21 Apr 2025
(DXR) Trading Report - news.stocktradersdaily.com

Fri, 18 Apr 2025
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire

Thu, 17 Apr 2025
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82% - Groundbreaking Clinical Results Unveiled - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	0 (M)
Shares Float	5 (M)
Held by Insiders	2.11e+006 (%)
Held by Institutions	57 (%)
Shares Short	12 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-36.41
Profit Margin	448 %
Operating Margin	-2 %
Return on Assets (ttm)	368.6 %
Return on Equity (ttm)	-2.6 %
Qtrly Rev. Growth	119710 %
Gross Profit (p.s.)	0
Sales Per Share	0.03
EBITDA (p.s.)	0
Qtrly Earnings Growth	-0.1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-0.22
Price to Sales	230.12
Price to Cash Flow	-0.07

Dividend	0
Forward Dividend	12910
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.